FR2726764B1 - ADJUVANT FOR VACCINE COMPOSITION - Google Patents
ADJUVANT FOR VACCINE COMPOSITIONInfo
- Publication number
- FR2726764B1 FR2726764B1 FR9413606A FR9413606A FR2726764B1 FR 2726764 B1 FR2726764 B1 FR 2726764B1 FR 9413606 A FR9413606 A FR 9413606A FR 9413606 A FR9413606 A FR 9413606A FR 2726764 B1 FR2726764 B1 FR 2726764B1
- Authority
- FR
- France
- Prior art keywords
- grouping
- vaccine composition
- adjuvant
- cationic
- lipophilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
An amphipathic compound including a sterol-derived lipophilic grouping bound to a cationic grouping for use as an adjuvant in the delivery of a vaccine composition. In a particular embodiment, the lipophilic grouping is a cholesterol derivative and the cationic grouping is a quaternary ammonium or a protonatable amine. A vaccine composition including one or more antigens with at least one amphipathic compound having a sterol-derived lipophilic grouping bound to a cationic grouping, is also disclosed.
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9413606A FR2726764B1 (en) | 1994-11-14 | 1994-11-14 | ADJUVANT FOR VACCINE COMPOSITION |
DE69529684T DE69529684T2 (en) | 1994-11-14 | 1995-11-14 | Vaccine adjuvants |
NZ297032A NZ297032A (en) | 1994-11-14 | 1995-11-14 | An amphipathic adjuvant for a vaccine includes a sterol derived lipohilic cholesterol bound to a cationic quaternary ammonium or a protonateable amine |
ES95940309T ES2187580T3 (en) | 1994-11-14 | 1995-11-14 | ADJUSTER FOR VACCINE COMPOSITION. |
PT95940309T PT793484E (en) | 1994-11-14 | 1995-11-14 | ADJUVANT FOR VACCINE COMPOSITION |
US08/836,576 US6780421B1 (en) | 1994-11-14 | 1995-11-14 | Adjuvant for a vaccine composition |
AU41802/96A AU706131B2 (en) | 1994-11-14 | 1995-11-14 | Adjuvant for a vaccine composition |
AT95940309T ATE232720T1 (en) | 1994-11-14 | 1995-11-14 | ADJUVANT FOR VACCINE |
MX9703505A MX9703505A (en) | 1994-11-14 | 1995-11-14 | Adjuvant for a vaccine composition. |
EP95940309A EP0793484B1 (en) | 1994-11-14 | 1995-11-14 | Adjuvant for a vaccine composition |
CA002205022A CA2205022C (en) | 1994-11-14 | 1995-11-14 | Adjuvant for a vaccine composition |
CN95196601A CN1096851C (en) | 1994-11-14 | 1995-11-14 | Adjuvant for a vaccine composition |
JP51580096A JP3923518B2 (en) | 1994-11-14 | 1995-11-14 | Adjuvant for vaccine composition |
DK95940309T DK0793484T3 (en) | 1994-11-14 | 1995-11-14 | Adjuvant to vaccine preparation. |
PCT/FR1995/001495 WO1996014831A1 (en) | 1994-11-14 | 1995-11-14 | Adjuvant for a vaccine composition |
US10/834,616 US20050002952A1 (en) | 1994-11-14 | 2004-04-29 | Adjuvant for vaccine composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9413606A FR2726764B1 (en) | 1994-11-14 | 1994-11-14 | ADJUVANT FOR VACCINE COMPOSITION |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2726764A1 FR2726764A1 (en) | 1996-05-15 |
FR2726764B1 true FR2726764B1 (en) | 1997-01-31 |
Family
ID=9468771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9413606A Expired - Fee Related FR2726764B1 (en) | 1994-11-14 | 1994-11-14 | ADJUVANT FOR VACCINE COMPOSITION |
Country Status (15)
Country | Link |
---|---|
US (2) | US6780421B1 (en) |
EP (1) | EP0793484B1 (en) |
JP (1) | JP3923518B2 (en) |
CN (1) | CN1096851C (en) |
AT (1) | ATE232720T1 (en) |
AU (1) | AU706131B2 (en) |
CA (1) | CA2205022C (en) |
DE (1) | DE69529684T2 (en) |
DK (1) | DK0793484T3 (en) |
ES (1) | ES2187580T3 (en) |
FR (1) | FR2726764B1 (en) |
MX (1) | MX9703505A (en) |
NZ (1) | NZ297032A (en) |
PT (1) | PT793484E (en) |
WO (1) | WO1996014831A1 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1271992C (en) | 1996-05-08 | 2006-08-30 | 尼卡健康产品有限公司 | Cationic virosomes as transfer system for genetic material |
DE19631189A1 (en) * | 1996-08-02 | 1998-02-05 | Max Delbrueck Centrum | Novel cationic amphiphiles for liposomal gene transfer |
FR2781160B1 (en) * | 1998-07-03 | 2000-08-18 | Pasteur Merieux Serums Vacc | USE OF AN AMPHIPATHIC COMPOUND TO ADJUST A SUBUNIT VACCINE |
US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
CA2340330A1 (en) | 1998-08-20 | 2000-03-02 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein c of chlamydia |
US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
WO2000066739A2 (en) | 1999-05-03 | 2000-11-09 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
FR2797188A1 (en) * | 1999-08-04 | 2001-02-09 | Univ Paris Nord Laboratoire De | CATIONIC LIPID COMPOUNDS AND THEIR USE FOR THE TRANSFER OF NEGATIVELY CHARGED SUBSTANCES OF THERAPEUTIC INTEREST |
WO2001030847A1 (en) | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
EP1792995A3 (en) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia secretory locus orf and uses thereof |
AU5810201A (en) | 2000-05-10 | 2001-11-20 | Aventis Pasteur | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
US7713942B2 (en) * | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
US20060165717A1 (en) * | 2005-01-25 | 2006-07-27 | Sanofi Pasteur | DCchol in newborns |
FR2881050B1 (en) * | 2005-01-25 | 2007-02-23 | Sanofi Pasteur Sa | DCCHOL IN THE NEW-NES |
EP2495327B1 (en) | 2006-03-03 | 2016-09-28 | ProMIS Neurosciences Inc. | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US9598462B2 (en) | 2012-01-26 | 2017-03-21 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
WO2009029686A1 (en) | 2007-08-27 | 2009-03-05 | Longhorn Vaccines & Diagnostics Llc | Immunogenic compositions and methods |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
ES2528648T3 (en) | 2007-09-11 | 2015-02-11 | University Of Guelph | Polysaccharide immunogens from Clostridium Difficile |
CN101827613A (en) | 2007-09-27 | 2010-09-08 | 免疫疫苗技术有限公司 | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
CA2861667C (en) | 2007-10-01 | 2017-06-13 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system and methods of use |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
JP2011500730A (en) | 2007-10-26 | 2011-01-06 | ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント | Treatment and diagnostic method using Tim-3 |
RU2530555C2 (en) | 2008-04-17 | 2014-10-10 | ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН | Stimulation of immune response by enantiomers of cationic lipids |
EP2296696B1 (en) * | 2008-06-05 | 2014-08-27 | ImmunoVaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
GB201116248D0 (en) * | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
AU2012321022B2 (en) | 2011-10-06 | 2017-03-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
CN105101991A (en) | 2012-09-21 | 2015-11-25 | Pds生物科技公司 | Improved vaccine compositions and methods of use |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
WO2017079835A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Amyloid beta epitopes and antibodies thereto |
EP3374379A4 (en) | 2015-11-09 | 2019-05-15 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
US10774120B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
WO2017083820A1 (en) | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
IT201900007060A1 (en) | 2019-05-21 | 2020-11-21 | St Superiore Di Sanita | Engineered tumor cells and their uses |
IT201900012540A1 (en) | 2019-07-22 | 2021-01-22 | Humanitas Mirasole Spa | CHI3L1 inhibitors and their uses |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1502774A (en) * | 1974-06-25 | 1978-03-01 | Nat Res Dev | Immunological preparations |
US4261975A (en) * | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4971803A (en) * | 1985-04-08 | 1990-11-20 | California Institute Of Technology | Lamellar vesicles formed of cholesterol derivatives |
AU631377B2 (en) * | 1988-08-25 | 1992-11-26 | Liposome Company, Inc., The | Affinity associated vaccine |
US5100662A (en) | 1989-08-23 | 1992-03-31 | The Liposome Company, Inc. | Steroidal liposomes exhibiting enhanced stability |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
AU3614493A (en) * | 1992-02-04 | 1993-09-01 | Chiron Corporation | Non-toxic lipid vaccine formulations |
FR2732895B1 (en) * | 1995-04-11 | 1997-05-16 | Pasteur Merieux Serums Vacc | USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTING AGENT, AS A VACCINE ADDITIVE, OR AS A MEDICINAL PRODUCT |
-
1994
- 1994-11-14 FR FR9413606A patent/FR2726764B1/en not_active Expired - Fee Related
-
1995
- 1995-11-14 WO PCT/FR1995/001495 patent/WO1996014831A1/en active IP Right Grant
- 1995-11-14 AU AU41802/96A patent/AU706131B2/en not_active Ceased
- 1995-11-14 CN CN95196601A patent/CN1096851C/en not_active Expired - Fee Related
- 1995-11-14 AT AT95940309T patent/ATE232720T1/en active
- 1995-11-14 CA CA002205022A patent/CA2205022C/en not_active Expired - Fee Related
- 1995-11-14 US US08/836,576 patent/US6780421B1/en not_active Expired - Fee Related
- 1995-11-14 ES ES95940309T patent/ES2187580T3/en not_active Expired - Lifetime
- 1995-11-14 EP EP95940309A patent/EP0793484B1/en not_active Expired - Lifetime
- 1995-11-14 JP JP51580096A patent/JP3923518B2/en not_active Expired - Fee Related
- 1995-11-14 DE DE69529684T patent/DE69529684T2/en not_active Expired - Lifetime
- 1995-11-14 PT PT95940309T patent/PT793484E/en unknown
- 1995-11-14 NZ NZ297032A patent/NZ297032A/en not_active IP Right Cessation
- 1995-11-14 DK DK95940309T patent/DK0793484T3/en active
- 1995-11-14 MX MX9703505A patent/MX9703505A/en not_active IP Right Cessation
-
2004
- 2004-04-29 US US10/834,616 patent/US20050002952A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPH11500409A (en) | 1999-01-12 |
EP0793484A1 (en) | 1997-09-10 |
CN1096851C (en) | 2002-12-25 |
AU706131B2 (en) | 1999-06-10 |
EP0793484B1 (en) | 2003-02-19 |
MX9703505A (en) | 1997-07-31 |
AU4180296A (en) | 1996-06-06 |
JP3923518B2 (en) | 2007-06-06 |
DK0793484T3 (en) | 2003-06-02 |
CN1168629A (en) | 1997-12-24 |
DE69529684D1 (en) | 2003-03-27 |
DE69529684T2 (en) | 2003-09-18 |
PT793484E (en) | 2003-06-30 |
US6780421B1 (en) | 2004-08-24 |
CA2205022C (en) | 2009-12-22 |
NZ297032A (en) | 1999-11-29 |
WO1996014831A1 (en) | 1996-05-23 |
ATE232720T1 (en) | 2003-03-15 |
US20050002952A1 (en) | 2005-01-06 |
CA2205022A1 (en) | 1996-05-23 |
FR2726764A1 (en) | 1996-05-15 |
ES2187580T3 (en) | 2003-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2726764B1 (en) | ADJUVANT FOR VACCINE COMPOSITION | |
CO5070644A1 (en) | VACCINES INCLUDING PROTEINS E6 of HPV AND / OR E7 of HPV TOGETHER WITH A CPG OLIGONUCLEOTIDE AS ASSISTANT | |
DK0859632T3 (en) | Influenza Vaccine preparations | |
BR9506484A (en) | Neuraminidase recombines its process vector for its manufacture and use as an influenza vaccine | |
BR9510263A (en) | New cyclodextrin derivative process for its preparation using the same therapeutic and adjuvant composition for vaccines | |
EP0955059A3 (en) | Vaccines containing a saponin and a sterol | |
ES2186809T3 (en) | COMPOSITIONS OF VACCINES FOR INTRANASAL ADMINISTRATION, UNDERSTANDING CHITOSANA AND ITS USE. | |
ES2092306T3 (en) | ADJUVANT FOR VACCINES. | |
NO20002785D0 (en) | Adam Anta Derivatives | |
NO20002786D0 (en) | Adam Anta Derivatives | |
BR9611533A (en) | Lipopolyamine composition and use and process of preparing a lipopolyamine | |
SE9704546D0 (en) | Novel compounds | |
PT973511E (en) | UTILIZATION OF SIBUTRAMINE ANALOGS TO DOWNLOAD LIPID LEVELS | |
NO307877B1 (en) | Non-explosive water-in-oil emulsion fertilizer compositions | |
DE60015084D1 (en) | IMPROVEMENT OF THE BACTERICIDAL ACTIVITY OF NEISSERIA ANTIGEN WITH CG CONTAINING OLIGONUCLEOTIDES | |
ATE235886T1 (en) | HAIR AVIVIVATION PREPARATIONS | |
MA24794A1 (en) | D-METHADONE, A NONOPIOIC ANALGESIC | |
DE60114996D1 (en) | LOWERING OF THE SERUM CHOLESTEROL | |
DK0799035T3 (en) | Emulsion suitable for administration of a sphingolipid and its use | |
ATE283254T1 (en) | CYTOFECTIN DIMERS AND METHOD FOR USE THEREOF | |
DE60041351D1 (en) | GSSYTEM | |
TR200000154T2 (en) | 2,4,4-Trisubstituted-1,3-Dioxolan antifungal agents. | |
NL300165I2 (en) | Babesia vaccine. | |
FI945414A0 (en) | Process for the preparation of N, N-disubstituted aminophenol | |
FR2768928B1 (en) | LIPOSOMES COMPRISING FHA AND THEIR VACCINE USES, AND USE OF FHA FOR STIMULATION OF IMMUNE RESPONSES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CD | Change of name or company name | ||
ST | Notification of lapse |
Effective date: 20140731 |